Vestcor Inc Catalyst Pharmaceuticals, Inc. Transaction History

Vestcor Inc

$3.35 Billion
Q3 2025

A detailed history of Vestcor Inc transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Vestcor Inc holds 56,587 shares of CPRX stock, worth $1.31 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

56,587

Previous 61,647 8.21%

Holding current value

$1.31 Million

Previous $1.34 Million 16.67%

% of portfolio

0.03%

Previous 0.04%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	SELL	$19.13 - $22.22 $96,797 - $112,433	-5,060 Reduced 8.21%	56,587 $1.12 Million
Q2 2025 Aug 08, 2025	BUY	$21.4 - $26.31 $704,958 - $866,704	32,942 Added 114.76%	61,647 $1.34 Million
Q1 2025 May 08, 2025	BUY	$19.53 - $25.74 $16,405 - $21,621	840 Added 3.01%	28,705 $696,000
Q4 2024 Feb 10, 2025	SELL	$19.73 - $23.93 $642,527 - $779,304	-32,566 Reduced 53.89%	27,865 $582,000
Q3 2024 Nov 15, 2024	BUY	$15.19 - $21.35 $142,467 - $200,241	9,379 Added 18.37%	60,431 $1.2 Million

Q2 2024 Aug 13, 2024	BUY	$14.68 - $16.92 $368,776 - $425,047	25,121 Added 96.88%	51,052 $791,000
Q1 2024 May 14, 2024	SELL	$13.18 - $17.11 $434,109 - $563,552	-32,937 Reduced 55.95%	25,931 $413,000
Q4 2023 Feb 14, 2024	SELL	$11.78 - $17.29 $8,799 - $12,915	-747 Reduced 1.25%	58,868 $990,000
Q3 2023 Nov 14, 2023	BUY	$11.69 - $15.02 $92,841 - $119,288	7,942 Added 15.37%	59,615 $697,000
Q2 2023 Aug 15, 2023	BUY	$11.5 - $18.08 $77,728 - $122,202	6,759 Added 15.05%	51,673 $694,000
Q4 2022 Feb 15, 2023	BUY	$12.25 - $19.5 $121,115 - $192,796	9,887 Added 28.23%	44,914 $835,000
Q2 2022 Aug 15, 2022	BUY	$6.23 - $8.57 $218,218 - $300,181	35,027 New	35,027 $246,000

Others Institutions Holding CPRX

# of Institutions

390

Shares Held

105M

Call Options Held

164K

Put Options Held

439K

View Full List

About CATALYST PHARMACEUTICALS, INC.

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.38B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

More about CPRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vestcor Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vestcor Inc with notifications on news.

Account